MSR23 Health Economic Evaluations Alongside New Clinical Trial Designs – Results of an International Expert Panel Workshop

Cancer research is rapidly evolving with the proliferation of molecular targeted therapies. New types of adaptive, basket, and umbrella trials came to fore to assess innovative treatments tied to the existence of selected biomarkers rather than histological site. There is a lack of sound methodological guidance on conducting health economic evaluations alongside new trial designs. This study aims to investigate 1) how clinical evidence from such trials can be used in economic analyses, and 2) how HTA can respond to the paradigm shift in cancer research and development.